Corrected: BRIEF-Ionis Pharmaceuticals Q1 Revenue USD 246 Million Vs. IBES Estimate USD 195.6 Million
29/04/2026 12:00
Apr 29 (Reuters) - Ionis Pharmaceuticals Q1 operating expenses USD 364 million. Q1 operating income USD -118 million Q1 net income USD -93 million
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors